On February 28, 2018, David Kan, MD, Medical Director for Bright Heart Health, testified in front of the Energy and Commerce Committee in Washington, D.C.
Dr. Kan’s testimony focused on the following facts:
1. Addiction involving opioid use can be successfully treated with a combination of
medications and psychosocial interventions, and we have published standards and
guidelines that detail best practices for the use of these medications.
2. There are significant barriers to access these effective medications, resulting in a
significant addiction treatment gap in our country.
3. Changes to the Controlled Substances Act to facilitate the use of telemedicine and new
medication formulations can expand access to evidence-based treatment options and
help close the addiction treatment gap.